SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (date of earliest event reported): May 30, 2007
COMMONWEALTH BIOTECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
| | | | |
| Virginia | | 001-13467 | | 56-1641133 |
(State or Other Jurisdiction of Incorporation | | (Commission File Number) | | (IRS Employer Identification No.) |
601 Biotech Drive
Richmond, Virginia 23235
(Address of principal executive offices)
Registrant’s telephone number, including area code: (804) 648-3820
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS. |
| (a) | Financial statements of businesses acquired. |
Not Applicable.
| (b) | Pro forma financial information. |
Not Applicable.
| (c) | Shell company transactions. |
Not Applicable.
| | |
| 99.1 | | Press release, dated May 30, 2007, announcing the receipt by Mimotopes Pty Ltd and GlycoSyn IRL of a grant of
NZ $715,000 to build specialist GMP peptide capabilities. |
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | | |
| | COMMONWEALTH BIOTECHNOLOGIES, INC. |
| | |
| | By: | | /s/ Paul D’Sylva, Ph.D. |
| | | | Paul D’Sylva |
| | | | Chief Executive Officer |
Dated: May 31, 2007
3
EXHIBIT INDEX
| | |
| Number | | Description of Exhibit |
| 99.1 | | Press release, dated May 30, 2007, announcing the receipt by Mimotopes Pty Ltd and GlycoSyn IRL of a grant of NZ $715,000 to build specialist GMP peptide capabilities. |
